AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL)

CUSIP: 05337G107

Q2 2015 13F Holders as of 30 Jun 2015

Type / Class
Equity / COM
Total 13F shares
15,712,922
Share change
-101,539
Total reported value
$255,175,334
Put/Call ratio
33%
Price per share
$16.24
Number of holders
94
Value change
-$139,341,078
Number of buys
69
Number of sells
49

Quarterly Holders Quick Answers

What is CUSIP 05337G107?
CUSIP 05337G107 identifies AAVL - AVALANCHE BIOTECHNOLOGIES IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) as of Q2 2015

As of 30 Jun 2015, AVALANCHE BIOTECHNOLOGIES IN - COM (AAVL) was held by 94 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 15,712,922 shares. The largest 10 holders included FMR LLC, VHCP Management, LLC, CADIAN CAPITAL MANAGEMENT, LP, MILLENNIUM MANAGEMENT LLC, BlackRock Fund Advisors, FRONTIER CAPITAL MANAGEMENT CO LLC, JPMORGAN CHASE & CO, Redmile Group, LLC, VANGUARD GROUP INC, and Invesco Ltd.. This page lists 94 institutional shareholders reporting positions in this security for the Q2 2015 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.